Market Research Logo

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016’, provides in depth analysis on T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted pipeline therapeutics.

The report provides comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Overview
Therapeutics Development
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Stage of Development
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Therapy Area
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Indication
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Products Glance
Late Stage Products
Early Stage Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Companies
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
Biotest AG
CEL-SCI Corporation
Fountain Biopharma Inc.
Immupharma Plc
Inovio Pharmaceuticals, Inc.
TaiMed Biologics Inc.
United Biomedical, Inc.
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
3BNC-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
forigerimod acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibalizumab second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAX-16H5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CD4 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMB-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tregalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-421 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Projects
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Featured News & Press Releases
Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study
May 24, 2016: Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
May 06, 2016: Antibody therapy opens door to potential new treatment for HIV
May 05, 2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs
Apr 27, 2016: Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial
Apr 27, 2016: Single Antibody Infusions Provide Durable Protection Against HIV-Like Virus in Monkeys
Mar 09, 2016: First European site opened in France and patient recruitment commences in Lupuzor pivotal phase III study
Feb 15, 2016: First US Patients Commence Dosing In Lupuzor Pivotal Phase III Study
Dec 15, 2015: Over 70 Lupus Specialists Gather in Paris for Lupuzor’s Phase III Investigators Meeting
Dec 07, 2015: Lupuzor Pivotal Phase III Trial Recruiting First US Lupus Patients
Nov 09, 2015: Biotest to present data from TREAT 2b trial at The American College of Rheumatology 2015 Annual Meeting
Nov 04, 2015: ImmuPharma Provides Lupuzor Phase III Pivotal Trial Update
Jul 27, 2015: Clinicaltrials.Gov Registration Of Lupuzor Pivotal Phase III Trial
Jun 25, 2015: Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of Innovation from CNRS for Lupuzor
Apr 24, 2015: Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Biotest AG, H2 2016
Pipeline by CEL-SCI Corporation, H2 2016
Pipeline by Fountain Biopharma Inc., H2 2016
Pipeline by Immupharma Plc, H2 2016
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Pipeline by TaiMed Biologics Inc., H2 2016
Pipeline by United Biomedical, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Dormant Projects (Contd..3), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report